Edition:
India

Nabriva Therapeutics PLC (NBRV.OQ)

NBRV.OQ on NASDAQ Stock Exchange Global Select Market

6.59USD
19 Jan 2018
Change (% chg)

$0.06 (+0.92%)
Prev Close
$6.53
Open
$6.58
Day's High
$6.64
Day's Low
$6.45
Volume
30,834
Avg. Vol
163,588
52-wk High
$14.09
52-wk Low
$4.77

Chart for

About

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel... (more)

Overall

Beta: --
Market Cap(Mil.): $304.02
Shares Outstanding(Mil.): 36.63
Dividend: --
Yield (%): --

Financials

BRIEF-Nabriva Therapeutics reports Q3 loss per share $0.79

* Nabriva Therapeutics reports third quarter 2017 financial results and recent corporate highlights

09 Nov 2017

BRIEF-Nabriva Therapeutics announces pricing of public offering of ordinary shares of nearly $80 mln

* Nabriva Therapeutics announces pricing of public offering of ordinary shares of approximately $80 million

20 Sep 2017

Nabriva's pneumonia drug succeeds in late-stage trial, shares soar

Nabriva Therapeutics Plc shares nearly doubled in morning trading on Monday after the company said its experimental antibiotic for community-acquired bacterial pneumonia (CABP) met the main goal of a late-stage study.

18 Sep 2017

BRIEF-Nabriva therapeutics announces positive topline results

* Nabriva Therapeutics announces positive topline results from global, phase 3 clinical trial evaluating IV and oral lefamulin for the treatment of community-acquired bacterial pneumonia

18 Sep 2017

BRIEF-Nabriva Therapeutics reports Q2 loss per share $0.54

* Nabriva Therapeutics reports second quarter 2017 financial results and recent corporate highlights

07 Aug 2017

BRIEF-Nabriva Therapeutics files for mixed shelf of upto $175 mln - SEC Filing

* Files for mixed shelf of upto $175 million - SEC Filing Source text: [http://bit.ly/2v5i1V5] Further company coverage:

29 Jul 2017

Earnings vs. Estimates